

PATIENT NAME : MOHIT SINGH	AL	REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)		
CODE/NAME & ADDRESS : C000138	364	ACCESSION NO : 0321WE002161	AGE/SEX : 35 Years Male	
ACROFEMI HEALTHCARE LTD (MEI	•	PATIENT ID : MOHIM080188321	DRAWN :13/05/2023 00:00:00	
F-703, LADO SARAI, MEHRAULISO DELHI	UTH WEST	ABHANDATIENT ID:	RECEIVED : 13/05/2023 07:51:00	
NEW DELHI 110030		ABHA NO :	REPORTED :18/05/2023 12:13:37	
8800465156				
Test Report Status <u>Final</u>		Results Biolog	jical Reference Interval Units	
MEDI WHEEL FULL BODY HEALT		OW 40 MALE		
XRAY-CHEST	II CILLER OF DEL			
IMPRESSION		NO ABNORMALITY DETECTED		
TMT OR ECHO				
TMT OR ECHO		2D ECHO:-		
		1) NORMAL CHAMBERS AND VALVES.		
		2) GOOD LV SYSTOLIC FUNCTION.	LVEF 60%. NO RWMA AT REST.	
		3) NO MR, AR, TR.		
		4) NORMAL LV COMPLIANCE.		
		5) NO PAH.		
		6) NO LV CLOT, VEGETATION OR P	ERICARDIAL EFFUSION.	
		7) IAS/IVS INTACT.		
ECG				
ECG		NORMAL SINUS RHYTHM		
MEDICAL HISTORY				
RELEVANT PRESENT HISTORY		NOT SIGNIFICANT		
RELEVANT PAST HISTORY		P/H/O TUBERCULOSIS LYMPH NOD	E 1 YEARS BACK	
		SPINAL SURGERY (L4 - L5) SEPTE	MBER 2021	
RELEVANT PERSONAL HISTORY		NOT SIGNIFICANT		
RELEVANT FAMILY HISTORY		NOT SIGNIFICANT		
OCCUPATIONAL HISTORY		NOT SIGNIFICANT		
HISTORY OF MEDICATIONS		NOT SIGNIFICANT		
S	P. V. Kepadia		Page 1 Of 22	
Dr.Sahil .N.Shah	Dr.Priyank Kapadi	а		
Consultant Radiologist	Physician			

View Details



View Report



PATIENT NAME : MOHIT SINGHAL	REF. DOCTOR	: DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321WE002161 PATIENT ID : MOHIM080188321 SHFATNBATIENT ID:	AGE/SEX :35 Years Male DRAWN :13/05/2023 00:00:00 RECEIVED :13/05/2023 07:51:00 REPORTED :18/05/2023 12:13:37
Test Report Status <u>Final</u>	Results Biologic	al Reference Interval Units

ANTHROPOMETRIC	DATA & BMI
----------------	------------

HEIGHT IN METERS	1.77	mts
WEIGHT IN KGS.	80.8	Kgs
ВМІ	26	BMI & Weight Status as follows/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE	NORMAL
PHYSICAL ATTITUDE	NORMAL
GENERAL APPEARANCE / NUTRITIONAL STATUS	OVERWEIGHT
BUILT / SKELETAL FRAMEWORK	TALL STATURE
FACIAL APPEARANCE	NORMAL
SKIN	NORMAL
UPPER LIMB	NORMAL
LOWER LIMB	NORMAL
NECK	NORMAL
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER
THYROID GLAND	NOT ENLARGED
TEMPERATURE	NORMAL
PULSE	68//MIN
RESPIRATORY RATE	NORMAL

CARDIOVASCULAR SYSTEM

Dr.Sahil .N.Shah **Consultant Radiologist** p v. Kapadia

Dr.Priyank Kapadia Physician

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Guirat India Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 ${\sf Email: customercare.ahmedabad@srl.in}$

Page 2 Of 22

-1



View Details

译母: 回路 View Report





Patient Ref. No. 775000003205056

			ulughostics
PATIENT NAME : MOHIT SINGHAL			CROFEMI HEALTHCARE LTD
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321		SEX : 35 Years Male
ACROFEMI HEALTHCARE LTD (MEDIWHEEL		IM080188321 DRAV	WN :13/05/2023 00:00:00
F-703, LADO SARAI, MEHRAULISOUTH WE DELHI	EST	RECE	EIVED : 13/05/2023 07:51:00
NEW DELHI 110030		1	DRTED :18/05/2023 12:13:37
8800465156			
Test Report Status <u>Final</u>	Results	Biological Refe	rence Interval Units
BP	126/82 MM HG (SITTING)		mm/Hg
PERICARDIUM	NORMAL		
APEX BEAT	NORMAL		
HEART SOUNDS	S1, S2 HEARD NORM	IALLY	
MURMURS	ABSENT		
	NODMAL		
SIZE AND SHAPE OF CHEST	NORMAL		
MOVEMENTS OF CHEST	SYMMETRICAL		
BREATH SOUNDS INTENSITY	NORMAL		
BREATH SOUNDS QUALITY	VESICULAR (NORMAL	_)	
ADDED SOUNDS	ABSENT		
PER ABDOMEN			
APPEARANCE	NORMAL		
LIVER	NOT PALPABLE		
SPLEEN	NOT PALPABLE		
CENTRAL NERVOUS SYSTEM			
HIGHER FUNCTIONS	NORMAL		
	NORMAL		
CRANIAL NERVES	NORMAL		
CEREBELLAR FUNCTIONS			
SENSORY SYSTEM	NORMAL		
MOTOR SYSTEM	NORMAL		
REFLEXES	NORMAL		
- P.V.	topulia		
\rightarrow			Page 3 Of 22
Dr.Sahil .N.Shah Dr.Priya Consultant Radiologist Physicia	yank Kapadia ian		View Details View Report



PATIENT NAME : MOHIT SINGHAL	REF. DOCTOR : [(DR. ACROFEMI HEALTHCARE LTD MEDIWHEEL)
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321WE002161 РАПЕНТ ID : MOHIM080188321 GEIENT BATIENT ID:	AGE/SEX :35 Years Male DRAWN :13/05/2023 00:00:00 RECEIVED :13/05/2023 07:51:00 REPORTED :18/05/2023 12:13:37
Test Report Status Final	Results Biological	Reference Interval Units

MUSCULOSKELETAL SYSTEM

SPINE	NORMAL
JOINTS	NORMAL

BASIC EYE EXAMINATION

DISTANT VISION RIGHT EYE WITHOUT	WITHIN NORMAL LIMIT
GLASSES	
DISTANT VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT
NEAR VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT
NEAR VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT
	NORMAI
COLOUR VISION	NORMAL

SUMMARY

RELEVANT HISTORY	NOT SIGNIFICANT
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT
RELEVANT LAB INVESTIGATIONS	HDL:- LOW
RELEVANT NON PATHOLOGY DIAGNOSTICS	NO ABNORMALITIES DETECTED
REMARKS / RECOMMENDATIONS	NONE

Comments

OUR PANEL DOCTORS FOR NON-PATHOLOGY TESTS:-CHECK UP DONE BY:- DR. NAMRATA AGRAWAL (M.B.B.S) REPORT REVIEWED BY:- DR. PRIYANK KAPADIYA (M.B.B.S DNB MEDICINE) RADIOLOGIST:- DR. SAHIL N SHAH (M.D.RADIOLOGY)

Dr.Sahil .N.Shah Consultant Radiologist P. V. Kapadia

Dr.Priyank Kapadia Physician



View Report

Page 4 Of 22

View Details





PATIENT NAME : MOHIT SINGHAL	REF. DOCTOR : [DR. ACROFEMI HEALTHCARE LTD MEDIWHEEL)
F-703 LADO SARAT MEHRAULTSOUTH WEST	ACCESSION NO : 0321WE002161 РАПЕНТ ID : MOHIM080188321 СЪЧЕЛТВАПЕНТ ID:	AGE/SEX :35 Years Male DRAWN :13/05/2023 00:00:00 RECEIVED :13/05/2023 07:51:00 REPORTED :18/05/2023 12:13:37
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE **ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN**

NO ABNORMALITIES DETECTED

Interpretation(s)

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

Dr.Sahil .N.Shah **Consultant Radiologist**

p v. Kapadia

Dr.Priyank Kapadia Physician



View Report View Details

Page 5 Of 22



Test Report Status

Final



Biological Reference Interval Units

PATIENT NAME : MOHIT SINGHAL	REF. DOCTOR :	DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321WE002161 РАПЕНТ ID : MOHIM080188321 СЪГАЛ ВАПЕНТ ID:	AGE/SEX :35 Years Male DRAWN :13/05/2023 00:00:00 RECEIVED :13/05/2023 07:51:00 REPORTED :18/05/2023 12:13:37

Results

ŀ	HAEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP E	ELOW 40 MALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD : PHOTOMETRIC MEASUREMENT	13.6	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD : COULTER PRINCIPLE	4.61	4.5 - 5.5	mil/µL
WHITE BLOOD CELL (WBC) COUNT METHOD : COULTER PRINCIPLE	4.96	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD : COULTER PRINCIPLE	261	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD : CALCULATED	39.6 Low	40.0 - 50.0	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	86.0	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED	29.5	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED	34.3	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	14.6 High	11.6 - 14.0	%
MENTZER INDEX METHOD : CALCULATED PARAMETER	18.7		
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM	8.8	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD : OPTICAL IMPEDENCE & MICROCSOPY	57	40 - 80	%
LYMPHOCYTES METHOD : OPTICAL IMPEDENCE & MICROCSOPY	34	20 - 40	%

ajen

Dr.Miral Gajera Consultant Pathologist



Page 6 Of 22

View Report





PATIENT NAME : MOHIT SINGHAL	REF. DOCTOR	: DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321WE002161 PATIENT ID : MOHIM080188321 GLIENT BATIENT ID:	AGE/SEX :35 Years Male DRAWN :13/05/2023 00:00:00 RECEIVED :13/05/2023 07:51:00 REPORTED :18/05/2023 12:13:37
Test Report Status Final	Results Biologic	al Reference Interval Units

Results	Biological Reference	Interval Units
6	2.0 - 10.0	%
3	1.0 - 6.0	%
0	0 - 1	%
2.83	2.0 - 7.0	thou/µL
1.69	1.0 - 3.0	thou/µL
0.30	0.2 - 1.0	thou/µL
0.15	0 02 - 0 50	thou/µL
0.15	0.02 0.00	
0.00 Low	0.02 - 0.10	thou/µL
1.6		
	3 0 2.83 1.69 0.30 0.15 0.00 Low	6 2.0 - 10.0 3 1.0 - 6.0 0 0 - 1 2.83 2.0 - 7.0 1.69 1.0 - 3.0 0.30 0.2 - 1.0 0.15 0.02 - 0.50 0.00 Low 0.02 - 0.10

MORPHOLOGY	
RBC	NORMOCYTIC NORMOCHROMIC
METHOD : MICROSCOPIC EXAMINATION	
WBC	NORMAL MORPHOLOGY
METHOD : MICROSCOPIC EXAMINATION	
PLATELETS	ADEQUATE
METHOD : MICROSCOPIC EXAMINATION	
REMARKS	NO PREMATURE CELLS ARE SEEN. MALARIAL PARASITE NOT DETECTED.
METHOD : MICROSCOPIC EXAMINATION	

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

Dr.Miral Gajera Consultant Pathologist



Page 7 Of 22

1

View Details





PATIENT NAME : MOHIT SINGHAL		DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321WE002161 РАПЕНТ ID : MOHIM080188321 GLIFAN BATIENT ID:	AGE/SEX :35 Years Male DRAWN :13/05/2023 00:00:00 RECEIVED :13/05/2023 07:51:00 REPORTED :18/05/2023 12:13:37
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@srl.in

Page 8 Of 22

建母









Biological Reference Interval Units

PATIENT NAME : MOHIT SINGHAL		R. ACROFEMI HEALTHCARE LTD MEDIWHEEL)
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	PATIENT ID : MOHIM080188321	AGE/SEX :35 Years Male DRAWN :13/05/2023 00:00:00 RECEIVED :13/05/2023 07:51:00 REPORTED :18/05/2023 12:13:37

Results

	HAEMATOLOGY	(
MEDI WHEEL FULL BODY HEALTH C	HECK UP BELOW 40 MALE		
ERYTHROCYTE SEDIMENTATION RA BLOOD	TE (ESR),WHOLE		
E.S.R	10	0 - 14	mm at 1 hr
METHOD : WESTERGREN METHOD			

Interpretation(s)

Test Report Status

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Final

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

Dr.Miral Gajera **Consultant Pathologist**

Page 9 Of 22









PATIENT NAME : MOHIT SINGHAL		OR. ACROFEMI HEALTHCARE LTD MEDIWHEEL)
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321WE002161 РАПЕНТ ID : MOHIM080188321 Сыңалықапент ID:	AGE/SEX:35 YearsMaleDRAWN:13/05/202300:00:00RECEIVED:13/05/202307:51:00REPORTED:18/05/202312:13:37
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

	IMMUNOHAEMATOLOGY	
MEDI WHEEL FULL BODY HEALTH CH	IECK UP BELOW 40 MALE	
ABO GROUP & RH TYPE, EDTA WHO	E BLOOD	
ABO GROUP METHOD : TUBE AGGLUTINATION	TYPE B	
RH TYPE METHOD : TUBE AGGLUTINATION	POSITIVE	

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@srl.in



诺曼:





Test Report Status

Final



Biological Reference Interval Units

PATIENT NAME : MOHIT SINGHAL	REF. DOCTOR :	DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WE002161	AGE/SEX : 35 Years Male
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : MOHIM080188321	DRAWN :13/05/2023 00:00:00
DELHI	CHEAT BATTENT ID:	RECEIVED : 13/05/2023 07:51:00
NEW DELHI 110030		REPORTED :18/05/2023 12:13:37
8800465156		

Results

	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECK UP	BELOW 40 MALE		
GLUCOSE FASTING,FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD : HEXOKINASE	93	74 - 99	mg/dL
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDT BLOOD	A WHOLE		
HBA1C	5.5	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
METHOD : HPLC ESTIMATED AVERAGE GLUCOSE(EAG)	111.2	< 116.0	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA PPBS(POST PRANDIAL BLOOD SUGAR) METHOD : HEXOKINASE	80	70 - 140	mg/dL
LIPID PROFILE, SERUM			
CHOLESTEROL, TOTAL	162	Desirable: < 200 BorderlineHigh: 200 - 239 High: > or = 240	mg/dL
METHOD : ENZYMATIC, COLORIMETRIC			<i>.</i>
TRIGLYCERIDES	137	Desirable: < 150 BorderlineHigh: 150 - 199 High: 200 - 499 Very High: > or = 500	mg/dL
METHOD : ENZYMATIC. COLORIMETRIC			

METHOD : ENZYMATIC, COLORIMETRIC

Dr.Miral Gajera **Consultant Pathologist**









PATIENT NAME : MOHIT SINGHAL		REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 032 PATIENT ID : MOI	AGE/SEX :35 Years Male HIM080188321 DRAWN :13/05/2023 00:00 RECEIVED :13/05/2023 07:51 REPORTED :18/05/2023 12:13	:00 :00
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units	
HDL CHOLESTEROL	36 Low	< 40 Low mg/dL > or = 60 High	
CHOLESTEROL LDL	99	Adult levels: mg/dL Optimal < 100 Near optimal/above optimal: 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	
NON HDL CHOLESTEROL	126	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	
VERY LOW DENSITY LIPOPROTEIN	27.4	< or = 30 mg/dL	
CHOL/HDL RATIO	4.5 High	3.3 - 4.4	
LDL/HDL RATIO	2.8	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	

METHOD : CALCULATED

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for	ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India
Risk Category	
Extreme risk group	A.CAD with > 1 feature of high risk group
	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or =
	50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3.
	Familial Homozygous Hypercholesterolemia
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors
Low Risk	0-1 major ASCVD risk factors

Dr.Miral Gajera Consultant Pathologist



Page 12 Of 22

34**4**







PATIENT NAME : MOHIT SINGHAL	RI	F. DOCTOR : DR. A (MED	CROFEMI HEALTHCA DIWHEEL)	RE LTD
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321W PATIENT ID : MOHIMO SEIENT BATIENT ID :	80188321 DRA REC	E/SEX : 35 Years WN : 13/05/202: EIVED : 13/05/202: ORTED : 18/05/202:	3 07:51:00
Test Report Status <u>Final</u>	Results	Biological Ref	erence Interval	Units
Major ASCVD (Atherosclerotic cardiovascular dis 1 Age $>$ or $=$ 45 years in males and $>$ or $=$ 55 years in	,	ette smoking or tobaco	co use	

in a joi inse v 2 (interester otter	cal dio (abculai dibeabe)) 10011 1 0			
1. Age $>$ or $=$ 45 years in males and	d > or = 55 years in fem	ales	3. Current Ci	garette smoking or	tobacco use
2. Family history of premature ASC	CVD		4. High blood	d pressure	
5. Low HDL					
Newer treatment goals and statin in	nitiation thresholds bas	sed on th	e risk categor	ies proposed by LA	AI in 2020.
Risk Group Treatment Goals				Consider Drug T	herapy
	LDL-C (mg/dl)	Non-H	DL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (0	Optional goal	>OR = 50	>OR = 80
	< OR = 30)	< OR =	60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or =<="" td=""><td>60</td><td>> 30</td><td>>60</td></or></td></or>	<or =<="" td=""><td>60</td><td>> 30</td><td>>60</td></or>	60	> 30	>60
Very High Risk	<50	<80		>OR= 50	>OR= 80
High Risk	<70	<100		>OR= 70	>OR=100
Moderate Risk	<100	<130		>OR=100	>OR=130
Low Risk	<100	<130		>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.51	Upto 1.2	mg/dL
BILIRUBIN, DIRECT	0.19	Upto 0.2	mg/dL
METHOD : DIAZO COLORIMETRIC			
BILIRUBIN, INDIRECT	0.32	0.00 - 1.00	mg/dL
TOTAL PROTEIN	6.8	6.4 - 8.3	g/dL
METHOD : COLORIMETRIC			
ALBUMIN	4.7	3.5 - 5.2	g/dL
METHOD : BROMOCRESOL GREEN			
GLOBULIN	2.1	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO	2.2 High	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	20	0 - 40	U/L
METHOD : IFCC WITHOUT PYRIDOXAL PHOSPHATE			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	18	0 - 41	U/L
METHOD : IFCC WITHOUT PYRIDOXAL PHOSPHATE			
ALKALINE PHOSPHATASE	74	40 - 129	U/L
METHOD : COLORIMETRIC			
GAMMA GLUTAMYL TRANSFERASE (GGT)	20	8 - 61	U/L
METHOD : ENZYMATIC, COLORIMETRIC			
LACTATE DEHYDROGENASE	164	135 - 225	U/L
METHOD : UV ASSAY METHOD			

Dr.Miral Gajera Consultant Pathologist



Page 13 Of 22

View Report

View Details





PATIENT NAME : MOHIT SINGHAL	REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)			
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321WE002161 РАПЕНТ ID : MOHIM080188321 СЫТЕЛТ ВАПЕНТ ID:		E/SEX :35 Years Male AWN :13/05/2023 00:00:00 CEIVED :13/05/2023 07:51:00 PORTED :18/05/2023 12:13:37	
Test Report Status <u>Final</u>	Results	Biological Ref	erence Interval Units	
BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN	6	6 - 20	mg/dL	
CREATININE, SERUM CREATININE METHOD : JAFFE ALKALINE PICRATE	0.79	0.70 - 1.30	mg/dL	
BUN/CREAT RATIO BUN/CREAT RATIO	7.59	5.0 - 15.0		
URIC ACID, SERUM URIC ACID	6.5	3.4 - 7.0	mg/dL	
TOTAL PROTEIN, SERUM TOTAL PROTEIN METHOD : COLORIMETRIC	6.8	6.4 - 8.3	g/dL	
ALBUMIN, SERUM ALBUMIN METHOD : BROMOCRESOL GREEN	4.7	3.5 - 5.2	g/dL	

GLOBULIN

Dr.Miral Gajera Consultant Pathologist



Page 14 Of 22





PATIENT NAME : MOHIT SINGHAL	REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)			
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 032 PATIENT ID : MO SHENNBATIENT ID:	HIM080188321 DR RE	E/SEX : 35 Years RAWN : 13/05/2023 CEIVED : 13/05/2023 PORTED : 18/05/2023	07:51:00
Test Report Status <u>Final</u>	Results	Biological Re	ference Interval l	Jnits
GLOBULIN	2.1	2.0 - 4.1	g/c	IL
ELECTROLYTES (NA/K/CL), SERUM				
SODIUM, SERUM METHOD : ISE	144.0	136 - 145	mn	nol/L
POTASSIUM, SERUM METHOD : ISE	3.96	3.3 - 5.1	mn	nol/L
CHLORIDE, SERUM METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY	109 High	98 - 106	mn	nol/L

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Dr.Miral Gajera Consultant Pathologist











PATIENT NAME : MOHIT SINGHAL

REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

	-		-	
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WE002161	AGE/SEX	:35 Years	Male
	PATIENT ID : MOHIM080188321	DRAWN	:13/05/2023 (00:00:00
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ABLENT BATIENT ID:	RECEIVED	: 13/05/2023 (07:51:00
NEW DELHI 110030		REPORTED	:18/05/2023	12:13:37
8800465156				

Test Report Status Results **Biological Reference Interval** Units Final

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the alucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed,Alimentary Hypoglycemia,Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes). The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for

well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates

addiction are reported to interfere with some assay methods, falsely increasing results. 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is

recommended for detecting a hemoglobinopathy GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis,sometimes due to a viral infection,ischemia to the liver,chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

Dr.Miral Gaiera Consultant Pathologist



Page 16 Of 22

治母

View Details



Test Report Status



Biological Reference Interval Units

PATIENT NAME : MOHIT SINGHAL	REF. DOCTOR : [(DR. ACROFEMI HEALTHCARE LTD MEDIWHEEL)
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321WE002161 PATIENT ID : MOHIM080188321 SHENT PATIENT ID:	AGE/SEX :35 Years Male DRAWN :13/05/2023 00:00:00 RECEIVED :13/05/2023 07:51:00 REPORTED :18/05/2023 12:13:37
Test Report Status Final	Results Biological	Reference Interval Units

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) **Causes of decreased** level include Liver disease, SIADH.

Final

CREATININE, SERUM-Higher than normal level may be due to: Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic

syndrome Causes of decreased levels-Low Zinc intake, CCP, Multiple Sclerosis TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms diseased. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr.Miral Gajera **Consultant Pathologist**

PERFORMED AT: Agilus Diagnostics Ltd (Formerly SRL Ltd) Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@srl.in

Page 17 Of 22





View Report

View <u>Details</u>





PATIENT NAME : MOHIT SINGHAL		REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)			
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156		АССЕSSION NO : 0321WE002161 РАПЕНТ ID : MOHIM080188321 ЕНЕМ ВАПЕНТ ID:		AGE/SEX :35 Years DRAWN :13/05/2023 RECEIVED :13/05/2023	/2023 00:00:00
				REPORTED :18/05/2023 12:13:37	
Test Report Status	Final	Results	Biological	Reference Interval	Units
	CLIN	ICAL PATH - URINALYSI	IS		
MEDI WHEEL FULL BO	DY HEALTH CHECK UP I	BELOW 40 MALE			
PHYSICAL EXAMINATI	ON, URINE				
COLOR		Yellow			
APPEARANCE		Clear			
CHEMICAL EXAMINATI	ION, URINE				
PH METHOD : REFLECTANCE SPECT	TROPHOTOMETRY	5.5	4.7 - 7.5		
SPECIFIC GRAVITY METHOD : REFLECTANCE SPECT	TROPHOTOMETRY	1.025	1.003 - 1.	035	
PROTEIN METHOD : REFLECTANCE SPECT	TROPHOTOMETRY	NOT DETECTED	NOT DETE	CTED	
GLUCOSE		NOT DETECTED	NOT DETE	CTED	

METHOD : REFLECTANCE SPECTROPHOTOMETRY

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION PUS CELL (WBC'S)	NOT DETECTED	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NORMAL

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NORMAL

KETONES

BILIRUBIN

NITRITE

UROBILINOGEN

LEUKOCYTE ESTERASE

BLOOD

Dr.Miral Gajera Consultant Pathologist



View Details



Page 18 Of 22

View Report



PATIENT NAME : MOHIT SINGHAL	REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)		
CODE/NAME & ADDRESS : C000138364 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321W РАПЕНТ ID : MOHIM SHENT BATIENT ID:	/E002161 080188321	AGE/SEX :35 Years Male DRAWN :13/05/2023 00:00:00 RECEIVED :13/05/2023 07:51:00 REPORTED :18/05/2023 12:13:37
Test Report Status <u>Final</u>	Results	Biologic	al Reference Interval Units
EPITHELIAL CELLS METHOD : MICROSCOPIC EXAMINATION	3-5	0-5	/HPF
CASTS METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED		
CRYSTALS METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED		
BACTERIA METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DE	TECTED
YEAST METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DE	TECTED
REMARKS	MICROSCOPIC EXAMIN CENTRIFUGED URINAR		INE IS CARRIED OUT ON

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions		
Proteins	Inflammation or immune illnesses		
Pus (White Blood Cells)) Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment		
Glucose	Diabetes or kidney disease		
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst		
Urobilinogen	Liver disease such as hepatitis or cirrhosis		
Blood	Renal or genital disorders/trauma		
Bilirubin	Liver disease		
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases		
Leukocytes Urinary tract infection, glomerulonephritis, interstitial nephracute or chronic, polycystic kidney disease, urolithiasis, congenital secretions			
Epithelial cells Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents bladder catheters for prolonged periods of time			
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein		

Dr.Miral Gajera Consultant Pathologist

Page 19 Of 22







PATIENT NAME : MOHIT SINGHAL

REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

	-		
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WE002161	AGE/SEX	:35 Years Male
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	PATIENT ID : MOHIM080188321	DRAWN	:13/05/2023 00:00:00
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ABIENT BATIENT ID:		: 13/05/2023 07:51:00
NEW DELHI 110030		REPORTED	:18/05/2023 12:13:37
8800465156			

|--|

Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases	
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice	
Uric acid	arthritis	
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.	
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis	

ojen

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 ${\sf Email: customercare.ahmedabad@srl.in}$

Page 20 Of 22







Biological Reference Interval Units

PATIENT NAME : MOHIT SINGHAL		DR. ACROFEMI HEALTHCARE LTD MEDIWHEEL)
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703 LADO SARAI MEHRAULISOUTH WEST	ACCESSION NO : 0321WE002161 PATIENT ID : MOHIM080188321 SETENT BATIENT ID:	AGE/SEX :35 Years Male DRAWN :13/05/2023 00:00:00 RECEIVED :13/05/2023 07:51:00 REPORTED :18/05/2023 12:13:37

Results

	est	Report	Status	Final
_				

	SPECIALISED CHEMISTRY - F	IORMONE			
MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE					
THYROID PANEL, SERUM					
T3 METHOD : ECLIA	115.90	80.0 - 200.0	ng/dL		
T4 METHOD : ECLIA	7.75	5.10 - 14.10	µg/dL		
TSH (ULTRASENSITIVE) METHOD : ECLIA	3.840	0.270 - 4.200	µIU/mL		

Interpretation(s)

Triiodothyronine T3, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Dr.Miral Gajera Consultant Pathologist





Page 21 Of 22





PATIENT NAME : MOHIT SINGHAL

REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

	(
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WE002161	AGE/SEX : 35 Years Male
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	PATIENT ID : MOHIM080188321	DRAWN :13/05/2023 00:00:00
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	SEIENT BATIENT ID:	RECEIVED : 13/05/2023 07:51:00
NEW DELHI 110030		REPORTED :18/05/2023 12:13:37
8800465156		

Т	est Report Status	<u>Final</u>	Results	Biological Reference Interval Units

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient
named or identified in the test requisition form.5.2. All tests are performed and reported as per the
turnaround time stated in the AGILUS Directory of Services.
3. Result delays could occur due to unforeseen
circumstances such as non-availability of kits / equipment
breakdown / natural calamities / technical downtime or any
other unforeseen event.5.

4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

 Test results cannot be used for Medico legal purposes.
In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Jeven

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India

Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@srl.in Page 22 Of 22





